Advertisement

Glycoconjugate Journal

, Volume 22, Issue 7–9, pp 395–400 | Cite as

Serum hyaluronidase aberrations in metabolic and morphogenetic disorders

  • Berta Fiszer-Szafarz
  • Barbara Czartoryska
  • Anna Tylki-Szymanska
Article

Abstract

Hyaluronidases are endo-glycosidases that degrade both hyaluronan (hyaluronic acid) (HA) and chondroitin sulfates. Deficiency of hyaluronidase activity has been predicted to result in a phenotype similar to that observed in mucopolysaccharidosis (MPS). In the present study, we surveyed a variety of patients with phenotypes similar to those observed in MPS, but without significant mucopolysacchariduria to determine if some are based on aberrations in serum hyaluronidase (Hyal-1) activity. The study included patients with well-characterized dysmorphic disorders occurring on genetic basis, as well as those of unkown etiology. The purpose of the study was to establish how wide spread were abnormalities in levels of circulating Hyal-1 activity. A simple and sensitive semi-quantitative zymographic procedure was used for the determination of activity. Levels of both ß -N-acetylglucosaminidase and ß -glucuronidase whose activities contribute to the total breakdown of hyaluronan (HA) were also measured, as well as the concentration of circulating HA. Among 48 patients with bone or connective tissue abnormalities, low levels of Hyal-1 activity were found in six patients compared to levels in 100 healthy donors (2.0–3.2 units/μL vs 6(± 1 SE) units/μL). These six patients exhibited a wide spectrum of clinical abnormalities, in particular shortened extremities: they included three patients with unknown causes of clinical symptoms, one patient with Sanfilippo disease, one of the seven patients with achondroplasia, and one with hypophosphotemic rickets. Normal levels of serum Hyal-1 activities were found in patients with Morquio disease, GM1 gangliosidosis, I cell-disease, 6 of the 7 patients with achondroplasia, Marfan's-syndrome and Ehlers-Danlos syndrome. No patient totally lacked serum Hyal-1 activity. Serum HA concentration was elevated in patients with Sanfilippo A and I-cell disease. Determination of serum and leukocyte Hyal-1 and serum HA may be useful to evaluate patients with metabolic and morphogenetic disorders.

Keywords

human serum hyaluronidase leukocyte hyaluronidase serum hyaluronan dysostosis-multiplex Sanfilippo-A disease achondroplasia hypophosphotemic rickets I-cell disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Neufeld EF, Meunzer J, The Mucopolysaccharidoses. In The Metabolic and Molecular Basis of Inherited Diseases, edited by Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, (McGraw-Hill, New York, 2001), 8th, pp. 3421–52.Google Scholar
  2. 2.
    Csoka AB, Scherer SW, Stern R, Expression analysis of six paralogous human hyaluronidase genes clustered on chromosomes 3p21 and 7q31, Genomics 60, 356–61 (1999).PubMedGoogle Scholar
  3. 3.
    Fiszer-Szafarz B, Szafarz D, Vannier P, Polymorphism of hyaluronidase in serum from man, various mouse strains and other vertebrate species revealed by electrophoresis, Biol Cell 68, 95–100 (1990).PubMedGoogle Scholar
  4. 4.
    Fiszer-Szafarz B, Vannier P, Litynska A, Zou L, Czartoryska B, Tilki Szymanska A, Hyaluronidase in human somatic tissues and urine: polymorphism and the activity in diseases, Acta Bioch Pol 42, 31–4 (1995).Google Scholar
  5. 5.
    Fiszer-Szafarz B, Litynska A, Zou L, Human hyaluronidases: electrophoretic multiple forms in somatic tissues and body fluids. Evidence for conserved hyaluronidase potential N-glycosylation sites in different mammalian species, J Biochem Biophys Methods 45, 103–16 (2000).PubMedCrossRefGoogle Scholar
  6. 6.
    Fiszer-Szafarz B, Litynska A, Zou L, Human hyaluronidase polymorphism and evidence for conserved hyaluronidase glycosylation sites in mammalian and non-mammalian species. In Hyaluronan. Chemical, biochemical and biological aspects, edited by Kennedy JF, Phillips GO, Williams PA, Hascall VC, (Woodhead Publishing Ltd, Cambridge, UK, 2002) 1, pp. 253–58.Google Scholar
  7. 7.
    Girard N, Maingonnat C, Bertrand P, Tilly H, Vannier JP, Delpech B, Human monocytes synthesize hyaluronidase, Brit J Haematol 119, 199–203 (2002).Google Scholar
  8. 8.
    Lepperdinger G, Strobl B, Kreil G, HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity. J Biol Chem 273, 22466–70 (1998).PubMedCrossRefGoogle Scholar
  9. 9.
    Stern R, Devising a pathway for hyaluronan catabolism. Are we there yet? Glycobiology, 13, 1–11 (2003).CrossRefGoogle Scholar
  10. 10.
    Stephens RW, Sutherland J, Ghosh P, Tailor TKF, Human serum and synovial fluid hyaluronidase. Bovine testicular hyaluronidase is not a valid structure in drug evaluation studies, Biochem Pharmacol 25, 1507–11 (1976).PubMedCrossRefGoogle Scholar
  11. 11.
    Berlepsch KV, Uber hyaluronidase und antihyaluronidase des menschlichen serums, Biochem Z 329, 542–8 (1958).Google Scholar
  12. 12.
    Fiszer-Szafarz B, Demonstration of a new hyaluronidase inhibitor in serum of cancer patients, Proc Soc Exp Biol 129, 300–02 (1968).Google Scholar
  13. 13.
    Glick D, Hyaluronidase inhibitor of human blood serum in health and disease, J Mt Sinai Hosp NY 17, 207–28 (1950).Google Scholar
  14. 14.
    Kulonen E, On hyaluronidase inhibitors in human blood, Acta Med Scand 136, 401–07 (1950)Google Scholar
  15. 15.
    Mio K, Stern R, Inhibitors of the hyaluronidases, Matrix Biol 21, 31–7 (2002).PubMedCrossRefGoogle Scholar
  16. 16.
    Kulyk WM, Kosher RA, Temporal and spatial analysis of hyaluronidase activity during development of the embryonic chick limb bud. Devop Biol 120, 535–41(1987).Google Scholar
  17. 17.
    Nathanson MA, Hyaluronates in developing skeletal tissues, Clin Orthop 251, 275–89 (1990).PubMedGoogle Scholar
  18. 18.
    Roden L, Campbell P, Fraser JR, Laurent TC, Pertoft H, Thompson JN, Enzymic pathways of hyaluronan catabolism. In The Biology of Hyaluronan, Ciba Foundation Symposium 143, edited by Evered D, Whelan J, (J Wiley & Sons, Chichester UK, 1989), pp. 60–86.Google Scholar
  19. 19.
    Liu DC, Pearlman E, Diaconu E, Guo K, Mori H, Haqqi T, Markowitz S, Willson J, Sy MS, Expression of hyaluronidase by tumor cells induces angiogenesis in vivo, Proc Natl Acad Sci USA, 93, 7832–37(1996).PubMedGoogle Scholar
  20. 20.
    Fiszer-Szafarz B, Effect of human cancerous serum on the chick embryo, Cancer Res 27, 191–7 (1967).PubMedGoogle Scholar
  21. 21.
    Nagaya H, Ymagata T, Ymagata S, Iyoda K, Ito H, Hasegawa Y, Iwata H. Examination of synovial fluid and serum hyaluronidase activity as a joint marker in rheumatoid arthritis and osteoarthritis patients (by zymography), Ann Rheum Dis 58, 186–88 (1999).PubMedCrossRefGoogle Scholar
  22. 22.
    Delpech B, Girard N, Bertrand P, Courel MN, Chauzy C, Delpech A, Hyaluronan: fundamental principles and applications in cancer, J Internal Med 242, 41–8 (1997).PubMedGoogle Scholar
  23. 23.
    Duran-Reynals F, Stewart FW, The action of tumor extracts on the spread of experimental vaccinia of the rabbit, Amer J Cancer 15, 2790–7 (1931).Google Scholar
  24. 24.
    Fiszer-Szafarz B, Gullino PM, Hyaluronidase activity of normal and neoplastic interstitial fluid, Proc Soc Exp Biol Med 133, 805–7 (1970).PubMedGoogle Scholar
  25. 25.
    Lundin A, Engström-Laurent A, Hällgren R, Michaëlsson G, Circulating hyaluronate in psoriasis, Brit J Dermatol 112, 663–71 (1985).Google Scholar
  26. 26.
    Longas MO, Wisch P, Lebwohl MG, Fleischmajer R, Glycosaminoglycans of skin and urine in pseudoxanthoma elasticum: evidence for chondroitin 6-sulfate alteration, Clin Chim Acta 155, 227–36 (1986).PubMedCrossRefGoogle Scholar
  27. 27.
    Neudecker BA, Stern R, Connolly MK, Aberrant serum hyaluronan and hyaluronidase levels in scleroderma, Brit J Dermatol 1, 469–76 (2004).Google Scholar
  28. 28.
    Natowicz MR, Short MP, Wang Y, Dickersin GR, Gebhardt MC, Rosenthal DI, Sims KB, Rosenberg AE, Clinical and biochemical manifestations of hyaluronidase deficiency, N Engl J Med 335, 1029–33 (1996).PubMedCrossRefGoogle Scholar
  29. 29.
    Triggs-Raine B, Salo TJ, Zhang H, Wicklow BA, Natowicz MR, Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX, Proc Natl Acad Sci USA 96, 6296–300 (1999).PubMedCrossRefGoogle Scholar
  30. 30.
    Kampine JP, Brady RO, Kanfer JN, Diagnosis of Gaucher disease and Nieman-Pick disease with small samples of venous blood, Science 155, 86–8 (1967).PubMedGoogle Scholar
  31. 31.
    Fiszer-Szafarz B, Hyaluronidase polymorphism detected by polyacrylamide gel electrophoresis. Application to hyaluronidases from bacteria, slime molds, bee and snake venoms, bovine testes, rat liver lysosomes, and human serum, Anal Biochem 143, 76–81 (1984).PubMedGoogle Scholar
  32. 32.
    Green MR, Pastewka JV, Identification of sialic acid-rich glycoproteins on polyacrylamide gels, Anal Biochem 65, 66–72 (1975).PubMedCrossRefGoogle Scholar
  33. 33.
    Glaser JH, Sly WS, ß -Glucuronidase deficiency mucopoysaccharidosis: method for enzymatic diagnosis, J Lab Clin Med 82, 969–77 (1973).PubMedGoogle Scholar
  34. 34.
    Hindman J, Cotlier E, Glycosidases in normal human leukocytes and abnormalities in GM1-gangliosidosis, Clin Chem 18, 971–8 (1972).PubMedGoogle Scholar
  35. 35.
    Delpech B, Bertrand P, Maingonnat C, Immunoenzyme assay of the hyaluronic acid-hyaluronectin interaction : application to the detection of hyaluronic acid in serum of normal subjects and cancer patients, Anal Biochem 149, 555–65 (1985).PubMedCrossRefGoogle Scholar
  36. 36.
    Pennock CA, A review and selection of simple laboratory methods used for the study of glycosaminoglycan excretion and diagnosis of mucopolysaccharidoses, J Clin Path 29, 111–23 (1976).PubMedGoogle Scholar
  37. 37.
    Natowicz MR, Wang Y, Plasma hyaluronidase activity in mucolipidosis II and III: marked differences from other lysosomal enzymes, Am J Med Genet, 65, 209–12 (1996).PubMedCrossRefGoogle Scholar
  38. 38.
    Creek KE, Sly WS, The role of the phosphomannosyl receptor in the transport of acid hydrolases to lysosomes. In Lysosomes in Biology and Pathology, edited by Dingle JT, Dean RT, Sly WS, (Elsevier Science Publishers, BV, Amsterdam, 1984), pp 63–82.Google Scholar
  39. 39.
    Bignami A, Hosley M, Dahl D, Hyaluronic acid and hyaluronic acid-binding proteins in brain extracellular matrix, Anat Embryol 188, 419–33 (1993).PubMedCrossRefGoogle Scholar
  40. 40.
    Ripellino JA, Margolis RU, Margolis RK, Immunoelectron microscopic localization of hyaluronic acid-binding region and link protein epitopes in brain, J Cell Biol 108, 1899–907 (1989).PubMedCrossRefGoogle Scholar
  41. 41.
    Kint JA, Secondarily induced lysosomal abnormalities in mucopolysaccharidoses, In The Developing Brain and its Disorders, edited by Arima M, Suzuki Y, Yabuuchi H (Univ. of Tokyo Press, Tokyo 1984), pp. 139–50.Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Berta Fiszer-Szafarz
    • 1
  • Barbara Czartoryska
    • 1
    • 2
  • Anna Tylki-Szymanska
    • 3
  1. 1.Institut Curie-BiologieCentre UniversitaireOrsayFrance
  2. 2.Department of GeneticsInstitute of Psychiatry and NeurologyWarsawPoland
  3. 3.Department of Metabolic DiseasesChildren's Memorial Health InstituteWarsawPoland

Personalised recommendations